Clinical trial · Observational
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors
NCT00885612CI-TRIAL-00003612completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.
- timeFrame
- 1 visit
Secondary outcomes (3)
- measure
- To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer
- timeFrame
- 1 Visit
- measure
- To analyse CHD management patterns according to defined 10-year CHD risk categories
- timeFrame
- 1 Visit
- measure
- To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk
- timeFrame
- 1 Visit
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Early Breast Cancer patients * Postmenopausal Status * patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months Exclusion Criteria: * Advanced Breast Cancer patients(stage iii, iv) * Patients who are hard to be analysed by limitation of chart record according to investigators discretion * patients who already have been registered in this study
References
Publications (0)
Data not yet available
No reference posted for this study.